STOCK WATCH

NEW ideas firm Frontier IP Group rose by nearly 10pc yesterday after entering a drug discovery partnership with pharmaceutical giant GlaxoSmithKline.

Frontier helps companies and universities bring their ideas and intellectual property to the market.

With funding from GSK, one of Frontier’s subsidiaries, Exscientia, will use robots to try and discover treatments for up to ten diseases.

Frontier’s shares rose 9.9pc, or 3.75p, to 41.75p.